Market Research Logo

US Tardive Dyskinesia Market: Size, Trends & Forecasts (2016-2025)

US Tardive Dyskinesia Market: Size, Trends & Forecasts (2016-2025)

Scope of the Report

The report entitled “US Tardive Dyskinesia Market: Size, Trends & Forecasts (2016-2025)”, provides analysis of the US tardive dyskinesia market, with detailed analysis of market size and growth, penetration, market share and economic impact of the industry. The report also provides the analysis of the major drugs (both existing and in pipeline) analysis, by penetrations, by revenue, etc.

Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall US tardive dyskinesia market has been forecasted for the years 2016-2025, taking into consideration the previous growth pattern, the growth drivers and the current and future trends.

Valeant Pharmaceuticals, Neurocrine Biosciences and Teva Pharmaceutical Industries are some of the key companies in the US tardive dyskinesia market. The company profiling of these companies has been done in the report, which includes business overview, financial overview and respective business strategies of the companies.

Company Coverage

Valeant Pharmaceuticals (Tertrabenazine)
Neurocrine Biosciences (Valbenazine)
Teva Pharmaceutical Industries (SD-809)

Executive Summary

Psychosis is a condition described as loss of contact with reality. And the people suffering from this condition are called psychotics. Some of the signs and symptom of psychosis are: difficulty in concentrating, depressed mood, sleeping too much or not enough, anxiety, etc. The two main types of psychiatric disorder related to tardive dyskinesia are Schizophrenia and Bipolar Disorder.

Involuntary movements of face, lips, tongue, extremities and trunk, is called tardive dyskinesia. This disease is caused by regular and long term intake of dopaminergic antagonist medications/ antipsychotics as a prescription for schizophrenia and bipolar disorder. Some of the signs and symptoms of tardive dyskinesia are grimacing, tongue movements, lip smacking, lip puckering, pursing of the lips, excessive eye blinking, etc.

Tardive dyskinesia has many different treatments, including vitamin E, benzodiazepines, levodopa, reserpine, botullinum toxin, tetrabenazine, dopamine-depleting agents, and calcium channel blockers. Along with these, two new treatments are in the pipeline: Valbenazine and SD-809.

The US tardive dyskinesia market is expected to increase at a significant growth rate during the forecasted period (2016-2025). The US tardive dyskinesia market is supported by various growth drivers, such as increase in number of schizophrenia patients, rising bipolar disorder patients, etc. Yet, the market faces certain challenges, such as, increased use of atypical antipsychotics, under-diagnosed market, side effects of drugs, etc.


1. Executive Summary
2. Introduction
2.1 Psychosis: An Overview
2.1.1 Psychosis
Table 1: Signs and Symptoms of Psychosis
2.1.2 Psychotic Disorder
Table 2: Psychiatric Disorder
2.1.3 Schizophrenia
2.1.4 Bipolar Disorder
2.2 Antipsychotics: An Overview
Table 3: Side Effects of Antipsychotics
2.3 Tardive Dyskinesia: An Overview
2.3.1 Signs and Symptoms
Table 4: Signs and Symptoms of Tardive Dyskinesia
2.3.2 Causes
2.3.3 Treatment
2.3.4 Existing and Pipeline Drugs
3. US Market Analysis
3.1 US Tardive Dyskinesia Market: An Analysis
3.1.1 US Tardive Dyskinesia Market by Number of Patients
Table 5: US Tardive Dyskinesia Market by Number of Patients; 2016-2020 (‘000)
3.1.2 US Tardive Dyskinesia Market Number of Patients by Segments
Table 6: US Tardive Dyskinesia Market Number of Patients by Segments; 2017
3.1.3 US Tardive Dyskinesia Market Number of Patients by Severity
Table 7: US Tardive Dyskinesia Market Number of Patients by Severity; 2016-2025 (‘000)
3.2 US Tardive Dyskinesia Drugs Market; An Analysis
3.2.1 US Valbenazine Market by Penetration
Table 8: US Valbenazine Market by Penetration; 2017-2025
3.2.2 US Valbenazine Market by Number of Patients
Table 9: US Valbenazine Market by Number of Patients and Compliance Rate; 2017-2025
3.2.3 US Valbenazine Market by Price and Revenue
Table 10: US Valbenazine Market by Price; 2017-2025 US$)
Table 11: US Valbenazine Market by Revenue; 2017-2025 (US$ Million)
3.2.4 US SD-809 Market by Penetration
Table 12: US SD-809 Market by Penetration; 2019-2025
3.2.5 US Tetrabenazine Market (For TD) by Penetration
Table 13: US Tetrabenazine Market (For TD) by Penetration; 2017-2025
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increasing Schizophrenia Patients
Table 14: Schizophrenia Patients in the USW; 2017-2025 (‘000)
4.1.2 Rising Bipolar Disorder Patients
Table 15: Bipolar Disorder Patients in the US; 2017-2025 (‘000)
4.1.3 Growing Antipsychotics Prescription
Table 16: Antipsychotic Prescription; Jan13-Sep16 (‘000)
4.2 Challenges
4.2.1 Tardive Dyskinesia Prevalence by Drug Class
Table 17: Tardive Dyskinesia Prevalence by Drug Class
4.2.2 Side Effects of Drugs
4.2.3 Under-diagnosed
4.3 Market Trends
4.3.1 Medications Causing Tardive Dyskinesia
Table A: Medications Causing Tardive Dyskinesia
4.3.2 Diagnosis of Tardive Dyskinesia
5. Competitive Landscape
Table B: US Tardive Dyskinesia Market Players by Financial Comparison
6. Company Profiling
6.1 Valeant Pharmaceuticals (Tetrabenazine)
6.1.1 Business Overview
6.1.2 Financial Overview
Table 18: Valeant Revenue; 2010-2015 (US$ Billion)
Table 19: Valeant Revenue by Segments; 2015
6.1.3 Business Strategy
Table C: Acquisitions of Valeant Pharmaceuticals
6.2 Neurocrine Biosciences, Inc. (Valbenazine)
6.2.1 Business Overview
6.2.2 Financial Overview
Table 20: Neurocrine Revenue; 2011-2015 (US$ Million)
Table 21: Neurocrine Research and Development Expense; 2013-2015 (US$ Million)6.2.3 Business Strategy
6.3 Teva Pharmaceuticals Industries Ltd. (SD-809)
6.3.1 Business Overview
6.3.2 Financial Overview
Table 22: Teva Revenue; 2011-2015 (US$ Billion)
Table 23: Teva Revenues by Segment; 2015
6.3.3 Business Strategy

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report